Evidence map›Paper›PMID 41781709›Full record

ArticleNature immunology2026

HLA class I signal peptide variation predicts strength of NKG2A

Zhansong Lin, Arman A Bashirova, Cian Callahan, George W Nelson, Emma Robinson, Mathias Viard, Minzhong Tang, Allan Hildesheim, Andre Franke, John D Rioux and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhansong Lin *Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Arman A Bashirova *Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Cian CallahanLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
George W NelsonBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Emma RobinsonBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Mathias ViardBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Minzhong TangKey Laboratory of Nasopharyngeal Carcinoma Molecular Epidemiology, Wuzhou Red Cross Hospital, Wuzhou, China.
Allan HildesheimAgencia Costarricense de Investigaciones Biomedicas, San Jose, Costa Rica.ORCID http://orcid.org/0000-0003-0257-2363
Andre FrankeInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0003-1530-5811
John D RiouxMontreal Heart Institute Research Centre, Université de Montréal, Montreal, Quebec, Canada.
Wilfredo Garcia-BeltranDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Mary CarringtonBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA. carringm@mail.nih.gov.ORCID http://orcid.org/0000-0002-2692-2180

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells expressing inhibitory receptors that recognize self human leukocyte antigen (HLA) class I molecules gain enhanced functionality-a process influenced by genetic polymorphism that dictates the strength of interactions between inhibitory receptors and their HLA ligands. Inhibitory CD94/NKG2A binds HLA-E loaded with epitopes derived from polymorphic HLA class I signal peptides (SPs). We generated a metric, called SP score, that quantifies the overall strength of CD94/NKG2A-HLA-E interactions based on a person's SP genotype. SP scores correlated positively with NKG2A

Indexed as

Histocompatibility Antigens Class IKiller Cells, NaturalNK Cell Lectin-Like Receptor Subfamily CProtein Sorting SignalsHLA-E AntigensHumansNK Cell Lectin-Like Receptor Subfamily DPolymorphism, GeneticHistocompatibility Antigens Class IHLA-E AntigensKLRC1 protein, humanNK Cell Lectin-Like Receptor Subfamily CNK Cell Lectin-Like Receptor Subfamily DProtein Sorting Signals

Identifiers

PMID41781709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.